Citigroup Inc Esperion Therapeutics, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 166,004 shares of ESPR stock, worth $400,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares

166,004

Previous 50,031 231.8%

Holding current value

$400,069

Previous $111,000 145.95%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.61 - $2.73 $186,716 - $316,606	115,973 Added 231.8%	166,004 $273,000
Q2 2024 Aug 12, 2024	SELL	$1.84 - $3.24 $564,359 - $993,763	-306,717 Reduced 85.98%	50,031 $111,000
Q1 2024 May 10, 2024	SELL	$2.02 - $3.02 $42,910 - $64,153	-21,243 Reduced 5.62%	356,748 $956,000
Q4 2023 Feb 09, 2024	BUY	$0.73 - $3.08 $265,032 - $1.12 Million	363,058 Added 2431.25%	377,991 $1.13 Million
Q3 2023 Nov 09, 2023	SELL	$0.96 - $1.79 $264 - $494	-276 Reduced 1.81%	14,933 $14,000
Q2 2023 Aug 10, 2023	SELL	$1.2 - $1.76 $29,662 - $43,505	-24,719 Reduced 61.91%	15,209 $21,000
Q1 2023 May 11, 2023	BUY	$1.46 - $7.3 $35,415 - $177,076	24,257 Added 154.79%	39,928 $63,000
Q4 2022 Feb 09, 2023	BUY	$5.09 - $8.5 $13,330 - $22,261	2,619 Added 20.07%	15,671 $97,000
Q3 2022 Nov 10, 2022	BUY	$5.45 - $8.13 $43,768 - $65,292	8,031 Added 159.95%	13,052 $87,000
Q2 2022 Aug 10, 2022	BUY	$4.77 - $6.67 $7,522 - $10,518	1,577 Added 45.79%	5,021 $32,000
Q1 2022 May 12, 2022	SELL	$3.34 - $5.56 $37,397 - $62,255	-11,197 Reduced 76.48%	3,444 $16,000
Q4 2021 Feb 10, 2022	BUY	$4.81 - $11.92 $45,964 - $113,907	9,556 Added 187.93%	14,641 $73,000
Q3 2021 Nov 10, 2021	BUY	$11.34 - $21.37 $57,663 - $108,666	5,085 New	5,085 $61,000

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account